Topline data from ORCA-1 trial expected in mid-2019 SEATTLE, Wash. and VANCOUVER, British Columbia, Feb. 20, 2019 — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced the completion of full enrollment in the ORCA-1 trial of cytisinicline. ORCA-1 is…
/Read More
SEATTLE, Wash. and VANCOUVER, British Columbia, Dec. 18, 2018 — Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today provided a clinical development update. The U.S. Food and Drug Administration (FDA) has confirmed that they are in agreement with Achieve’s Initial…
/Read More
Achieve Reports Financial Results for Third Quarter 2018 and Provides Cytisinicline (Cytisine) Clinical Development Update SEATTLE, Wash and VANCOUVER, British Columbia, November 7, 2018 — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today provided an update on the cytisinicline clinical…
/Read More
SEATTLE, Wash. and VANCOUVER, British Columbia, October 31, 2018 – – Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline (cytisine) for smoking cessation, today announced that it will report its third quarter 2018 financial results on Wednesday, November 7, 2018. Company management will host…
/Read More
SEATTLE, Wash. and VANCOUVER, British Columbia, October 30, 2018 – – Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced initiation of the Phase 2b ORCA-1 trial for smoking cessation. ORCA-1 is the first in Achieve’s ORCA (Ongoing Research of…
/Read More